Follicular lymphoma: today’s treatments and tomorrow’s targets
Autor: | Jane N. Winter, Vikas Aurora |
---|---|
Rok vydání: | 2006 |
Předmět: |
Oncology
Alkylating Agents medicine.medical_specialty medicine.medical_treatment Follicular lymphoma Antineoplastic Agents Cancer Vaccines Antibodies Monoclonal Murine-Derived Internal medicine Humans Immunologic Factors Medicine Pharmacology (medical) Lymphoma Follicular Randomized Controlled Trials as Topic Pharmacology Chemotherapy business.industry Patient Selection Hematopoietic Stem Cell Transplantation Antibodies Monoclonal General Medicine Radioimmunotherapy Prognosis medicine.disease Combined Modality Therapy Non-Hodgkin's lymphoma Transplantation Clinical trial Immunology Rituximab Interferons Refractory Follicular Lymphoma business medicine.drug |
Zdroj: | Expert Opinion on Pharmacotherapy. 7:1273-1290 |
ISSN: | 1744-7666 1465-6566 |
Popis: | Over the past two decades, the incidence of follicular lymphoma has increased. Contemporary treatments include combinations of chemotherapy and monoclonal antibodies, radioimmunotherapy, new targeted agents and stem-cell transplantation. Prognostic tools are becoming more important in helping clinicians and patients decide on the most appropriate therapeutic regimens. Gene expression profiling and biomarkers are promising additions to this armamentarium. When patients do require therapy, the addition of rituximab to chemotherapy seems to improve remission duration and may improve overall survival. Radioimmunotherapy capitalises on the capacity to target radiation directly to malignant cells, and is currently approved for the treatment of relapsed/refractory follicular lymphoma. Further investigation is needed to clarify the role of stem-cell transplantation in follicular lymphoma. Only well-designed clinical trials can provide answers to the many questions that remain regarding the optimal treatment and sequence of treatments for patients with follicular lymphoma. |
Databáze: | OpenAIRE |
Externí odkaz: |